{
    "relation": [
        [
            "",
            "Tesamorelin 52 Weeks",
            "Tesamorelin (26 Weeks) - Placebo (26 Weeks)",
            "Placebo (26 Weeks) - Tesamorelin (26 Weeks)"
        ],
        [
            "Description",
            "Tesamorelin 2 mg/day for 52 weeks",
            "Tesamorelin 2 mg/day for 26 weeks followed by Placebo for 26 weeks",
            "Placebo for 26 weeks followed by Tesamorelin 2 mg/day for 26 weeks"
        ]
    ],
    "pageTitle": "TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00608023?sect=X0125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042992201.62/warc/CC-MAIN-20150728002312-00210-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 861361055,
    "recordOffset": 861350666,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Tesamorelin Drug: Placebo for Tesamorelin Interventions: Lipodystrophy HIV Infections Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: November 27, 2013 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Tesamorelin (52 Weeks) \u00a0 \u00a0 Tesamorelin (26 Weeks) - Placebo (26 Weeks) \u00a0 \u00a0 Placebo-Tesamorelin (P-T) \u00a0 STARTED \u00a0 \u00a0 92 \u00a0 \u00a0 85 \u00a0 \u00a0 86 \u00a0 COMPLETED \u00a0 \u00a0 80 \u00a0 \u00a0 63 \u00a0 \u00a0 72 \u00a0 NOT COMPLETED \u00a0 \u00a0 12 \u00a0 \u00a0 22 \u00a0 \u00a0 14 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 8 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 10 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 7 \u00a0 Adverse Event \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}